20 Result(s)

Article

Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell disease

Allogeneic stem cell transplantation (Allo-SCT) is the only rapidly available curative treatment modality in patients with severe sickle cell disease (SCD). The development of reduced-toxicity myeloablative co...

Sabine Fürst, Emmanuelle Bernit, Faezeh Legrand… in Bone Marrow Transplantation (2024)

Article

Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome

Haploidentical stem cell transplantation (Haplo-SCT) using non-myeloablative conditioning regimen (NMAC) has extended the feasibility of allogeneic transplantation, notably in older patients. However, there is...

Samia Harbi, Louison Brac de la Perriere… in Bone Marrow Transplantation (2024)

Article

GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation

François Dachy, Sabine Furst, Boris Calmels… in Bone Marrow Transplantation (2023)

Article

Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies

Although post-transplant cyclophosphamide (PT-Cy) is effective for graft-versus-host disease (GVHD) prophylaxis, it is associated with toxicities, which might be dose-dependent. We compared the outcomes with P...

Rémy Duléry, Claire Goudet, Daniele Mannina… in Bone Marrow Transplantation (2023)

Article

Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide

Donor selection may contribute to improve clinical outcomes of T cell-replete haploidentical stem cell transplantation (Haplo-SCT) with post-transplant cyclophosphamide (PT-Cy). Impact of second-degree related...

Jacopo Mariotti, Anna Maria Raiola, Andrea Evangelista… in Bone Marrow Transplantation (2022)

Article

Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor

Allogeneic hematopoietic stem cell transplantation is the only potentially curative therapy for acute myeloid leukemia. In the absence of an HLA-matched related or unrelated donor (MRD or MUD), the best altern...

Clémence Deteix, Florence Mesnil, Sabine Furst, Noel Milpied… in Bone Marrow Transplantation (2020)

Article

Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation

Posttransplant cyclophosphamide (PT-Cy) is an efficient GVHD prophylaxis but has not been extensively evaluated in mismatched unrelated donor (MMUD) allo-HSCT, for which antithymocyte globulin (ATG) is still c...

Charlotte Nykolyszyn, Angela Granata, Thomas Pagliardini… in Bone Marrow Transplantation (2020)

Article

Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients

While bone marrow (BM) grafts were initially used for T-replete HLA-haploidentical related donors transplantation (Haplo-SCT) with post-transplantation cyclophosphamide (PT-Cy), the use of peripheral blood ste...

Angela Granata, Sabine Fürst, Stefania Bramanti… in Bone Marrow Transplantation (2019)

Article

The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide

We propose to test whether the new refined Minnesota risk score, which represents a new tool for acute Graft-versus-Host-Disease (aGVHD) grading, may be useful to predict the final outcome of patients with aGV...

Jacopo Mariotti, Angela Granata, Stefania Bramanti… in Bone Marrow Transplantation (2019)

Article

Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is limited by availability of HLA-matched sibling donors (MSDs). The alternative use of unrelated donors (UDs) is currently challenged by haploide...

Thomas Pagliardini, Samia Harbi, Sabine Fürst, Luca Castagna… in Bone Marrow Transplantation (2019)

Article

Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years

Due to limited donor availability, high comorbidities, and cost issues, allogeneic hematopoietic stem cell transplant is not universally accessible. The aim of this study was to conduct a cost-effectiveness an...

Mathias Debals-Gonthier, Carole Siani, Catherine Faucher… in Bone Marrow Transplantation (2018)

Article

Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma

Jacopo Mariotti, Stefania Bramanti, Raynier Devillier… in Bone Marrow Transplantation (2018)

Article

Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor

Different RIC regimens were evaluated prior to allo-HSCT in different hematological malignancies. We conducted this prospective study in adult patients with various hematological malignancies in order to evalu...

Mauricette Michallet, Mohamad Sobh, Noel Milpied… in Annals of Hematology (2012)